Skip to content

Decoding TL1A Blockade: Emerging Therapeutic Strategies for Bridging Critical Gaps in IBD Management
August 17, 2026 | TL1As Back2Basics
***Post-Survey & Application for CME Credit***

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.Where are you in your career? (Required.)
2.What is your community of practice?(Required.)
3.TL1A binds which receptor to drive intestinal inflammation and fibrosis in IBD?(Required.)
4.Which dose of Duvakitug showed endoscopic response of 48% vs 13% placebo (33% PP >0.99) at week 14 in patients with Crohn’s disease?(Required.)
EVALUATION FORM
5.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
Compare emerging TL1A-targeted therapies based on clinical trial efficacy, safety profiles, and potential patient populations.
6.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective.
The activity presented content relevant to my practice.
This activity promoted active learning (discussions, problem solving, case studies, etc.)
I was provided with useful resources to sustain improved skills/strategies, performance, and/or patient outcomes.
7.Overall, was this activity fair, balanced and free from commercial bias?
8.If no, please explain:
9.Of the patients you will see in the next month, about how many will benefit from the information you learned today?
10.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
11.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
12.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
13.I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Decoding TL1A Blockade: Emerging Therapeutic Strategies for Bridging Critical Gaps in IBD Management Tweetorial" and claim 1.0 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Privacy & Cookie Notice